Description

Montaz 250mg Injection is a combination antibiotic used to treat a wide range of moderate to severe bacterial infections. It contains Ceftriaxone, a third-generation cephalosporin, and Tazobactam, a beta-lactamase inhibitor. The addition of Tazobactam prevents bacterial resistance by inhibiting beta-lactamase enzymes, thereby enhancing Ceftriaxone’s effectiveness.

This strength (250mg) is often prescribed in pediatric cases or in patients requiring lower antibiotic doses.

Uses

Respiratory tract infections (pneumonia, bronchitis)
Ear, nose, and throat infections
Urinary tract infections (UTIs)
Skin and soft tissue infections
Bone and joint infections
Abdominal infections (peritonitis, post-surgical infections)
Septicemia (blood infections)
Gynecological infections
Bacterial meningitis (in children and adults)

How It Works

Ceftriaxone: Kills bacteria by preventing cell wall synthesis.
Tazobactam: Inhibits bacterial beta-lactamase enzymes that cause resistance, allowing Ceftriaxone to remain effective.

Together, they provide broad-spectrum coverage against Gram-positive and Gram-negative bacteria, including resistant strains.

Side Effects

Common:

Pain, redness, or swelling at injection site
Diarrhea, nausea, vomiting
Mild fever or rash

Serious (rare):

Severe allergic reactions (anaphylaxis, swelling, difficulty breathing)
Bloody or persistent diarrhea (Clostridium difficile infection)
Liver enzyme elevation, jaundice
Blood disorders (low platelets, anemia, leukopenia)

Precautions

Use cautiously in patients with kidney or liver impairment
Avoid in case of allergy to cephalosporins or penicillins
Newborns with jaundice (hyperbilirubinemia) should not receive Ceftriaxone
Safe use in pregnancy and breastfeeding only under doctor’s advice

Administration

Administered only by a healthcare professional via intravenous (IV) or intramuscular (IM) route
Dosage depends on age, weight, infection severity, and clinical condition
The 250mg dose is commonly used in children or low-dose requirements